Volition Sponsors Symposium on Nu.Q NETs Plasma Biomarker for Hidradenitis Suppurativa Treatment

Wednesday, Feb 4, 2026 8:46 am ET1min read
VNRX--

VolitionRx Limited sponsors a symposium at the European Hidradenitis Suppurativa Foundation Conference to present data on its Nu.Q® NETs assay in patient management for Hidradenitis Suppurativa. The assay can classify patients and guide treatment selection and modification. The study demonstrates the potential of Nu.Q® NETs as a biomarker for ongoing and future clinical studies, aiming to guide treatment initiation and cessation. The market opportunity for such indications is significant, with a Total Addressable Market of $3.8 billion.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet